Janssen Pharmaceuticals, Inc.

Glaxosmithkline Biologicals Sa

The University of Chicago

Jeroen Geurtsen

Eveline Marleen Weerdenburg

Darren Robert Abbanat

Jan Grijpstra

Pieter Jan Burghout

Michael T Kowarik

Stefan Jochen Kemmler

Manuela Mally

Patricia Ibarra Yon

Veronica Gambillara Fonck

Martin Edward Braun

Maria Paula Carranza Sandmeier

Kellen Cristhina Fae

Marleen Eveline Weerdenburg

Jan Theunis Poolman

Jakob Louris Feitsma

Jan Poolman

Cristhina Kellen Fae

Louris Jakob Feitsma

Olaf Schneewind

Dominique Missiakas

Carla Emolo

Molly McAdow

Mark De Been

Lena Thomer

Michal Sarnecki

Bart Gustaaf M Spiessens

Frank Germaine F Struyf

Michael Thomas Kowarik

Fonck Veronica Gambillara

Polypeptides comprising a FimH lectin domain comprising an amino acid mutation that causes the FimH lectin domain to be in the low affinity conformation for mannose are described. Pharmaceutical compositions which comprise such polypeptides and methods of stimulating an immune response in a subject in need thereof by administration of the polypeptide are further described.

FimH mutant, compositions therewith and use thereof

Polypeptides comprising a FimH lectin domain comprising at least one an amino acid mutation that causes the FimH lectin domain to be in the low affinity conformation for mannose are described. Pharmaceutical compositions which comprise such polypeptides and methods of stimulating an immune response in a subject in need thereof by administration of the polypeptide are further described.

FimH mutants, compositions therewith and use thereof

The invention pertains to host cells for producing a bioconjugate of anO18 antigen polysaccharide conjugated to a carrier protein. The host cells are characterized in that they comprise modified Wzy O-antigen polymerases with specific combinations of amino acid substitutions in one or more of positions 199, 377 and 395 as compared to the wild type Wzy O-antigen polymerase of SEQ ID NO: 1, which modified Wzy O-antigen polymerases improve the yield and glycosylation pattern of the O18 bioconjugates produced by the host cells. The invention further relates to methods wherein the host cells are used to produce a bioconjugate of anO18 antigen polysaccharide conjugated to a carrier protein, compositions comprising these bioconjugates, including multivalent compositions comprising bioconjugates of additional O antigen polysaccharide-serotypes.

Production of018 bioconjugates

Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic. (ExPEC).

Methods of producing bioconjugates ofO-antigen polysaccharides, compositions thereof, and methods of use thereof

Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic(ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates ofpolysaccharide antigen O75 covalently bound to a carrier protein for the prevention of invasive ExPEC disease.

Multivalent vaccine compositions and uses thereof

A bioconjugate of anglucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying theO4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of anglucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additionalO-antigen polysaccharides to induce antibodies against anglucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic(ExPEC).

Bioconjugates ofO-antigen polysaccharides, methods of production thereof, and methods of use thereof

Methods of producing bioconjugates ofo-antigen polysaccharides, compositions thereof, and methods of use thereof

[object Object]

Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by abacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody that binds Coagulase (Coa). Further aspects relate to immunogenic compositions comprising at least one Staphylococcal coagulase R Domain, wherein the R Domain is 80% identical in sequence to a R Domain.

Compositions and methods related to antibodies that neutralize coagulase activity duringdisease

Growing community of inventors

Vleuten, Netherlands

Jeroen Geurtsen